CD40L Pathway

The central role of CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation.


AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.

Clinical Development

Eledon Pharmaceuticals is building upon our deep understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies in renal transplantation, islet cell transplantation, IgA Nephropathy, and amyotrophic lateral sclerosis (ALS).

Nonclinical Development

We are dedicated to the highest ethical, humane and responsible treatment of animals necessary to the development of our medicines. We strive to replace the use of live animals, minimize the number of animals used, and refine our procedures to minimize distress, whenever scientifically possible and acceptable to regulators. We also work with our vendors to ensure their compliance with all applicable laws and regulations, as well as ethical best practices, related to animal-based research.